FDA logs an imlunestrant efficacy approval for ER-positive advanced breast cancer

The Food and Drug Administration has recorded a new efficacy approval for Inluriyo, Eli Lilly's oral breast-cancer drug imlunestrant. The action was logged in the agency's Drugs@FDA database on 18 September 2026 under new drug application 218881, held by Eli Lilly, as an efficacy supplement; the product is a tablet equivalent to 200 mg of imlunestrant base [s2]. The supplement's specific labelling text had not yet posted to the agency's public label file at the time of writing, so the account below rests on the pivotal trial itself rather than on new label language.

Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor degrader (SERD) designed to deliver continuous estrogen-receptor inhibition even in cancers carrying mutations in the gene encoding the receptor, ESR1 [s1]. Those mutations are a common route by which hormone-receptor-positive breast cancer escapes standard endocrine therapy, and the drug is designed to keep inhibiting the receptor even when they are present [s1]. That is the setting EMBER-3 was built to test — patients whose cancer had already recurred or progressed on earlier endocrine treatment [s1].

What the EMBER-3 trial tested

EMBER-3 was a phase 3, open-label trial in patients with estrogen-receptor-positive, HER2-negative advanced breast cancer that had recurred or progressed during or after an aromatase inhibitor, given alone or with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor [s1]. It randomly assigned 874 patients in a 1:1:1 ratio to imlunestrant alone, standard endocrine monotherapy, or imlunestrant plus the CDK4/6 inhibitor abemaciclib [s1][s3].

The trial set three progression-free-survival comparisons: imlunestrant versus standard therapy among patients with ESR1 mutations, the same comparison across all patients, and imlunestrant-abemaciclib versus imlunestrant alone among those randomised to that comparison [s1].

What it found

Among the 256 patients with ESR1 mutations, median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy; the restricted mean survival time at 19.4 months was 7.9 months (95% confidence interval 6.8 to 9.1) versus 5.4 months (4.6 to 6.2), a difference of 2.6 months (1.2 to 3.9; P<0.001) [s1].

The result was not uniform. In the overall population, median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy — a hazard ratio of 0.87 (95% CI 0.72 to 1.04; P=0.12) that did not reach significance [s1]. The clearest separation came from the combination: among 426 patients, imlunestrant-abemaciclib reached a median of 9.4 months versus 5.5 months for imlunestrant alone (hazard ratio 0.57; 95% CI 0.44 to 0.73; P<0.001) [s1].

That gain came with more toxicity. Grade 3 or higher adverse events occurred in 17.1% of patients on imlunestrant, 20.7% on standard therapy, and 48.6% on the imlunestrant-abemaciclib combination [s1].

How to read it

The honest summary is that imlunestrant alone beat standard endocrine therapy where the biology predicted it would — in ESR1-mutated disease — but not across all comers [s1]. The combination's larger benefit is real, but so is its near-tripling of grade 3-or-higher events, and the two have to be weighed together rather than read from the survival curve alone [s1].

Because the gains are measured in months of delayed progression rather than in cure, the practical question is which patients — defined by ESR1 status and prior treatment — stand to benefit enough to justify the added toxicity of adding abemaciclib [s1].

The trial's three-arm design is unusual, and it is what lets the data separate two questions that are easy to conflate: whether imlunestrant on its own improves on standard endocrine therapy, and whether combining it with a CDK4/6 inhibitor improves on imlunestrant alone [s1]. The answers diverged. The monotherapy advantage was confined to ESR1-mutated disease, where the biological rationale for a degrader that keeps working against a mutated receptor is strongest, while the overall-population comparison came up short [s1]. That pattern argues for testing ESR1 status rather than treating all comers the same way.

What to watch

The near-term questions are how the new labelling frames the eligible population and the combination, and whether overall-survival data, still maturing, follow the progression-free-survival signal [s1]. Imlunestrant is one of several oral SERDs competing for the post-CDK4/6 setting, and its place will be set by those longer-term numbers.

Red flags: patients on imlunestrant, especially with abemaciclib, who develop persistent diarrhoea, signs of dehydration, or new breathlessness should seek medical care promptly [s1]. This article describes research and regulatory news and is not medical advice. Cancer-treatment decisions are for patients and their treating oncologists.

Sources

• Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (EMBER-3) — New England Journal of Medicine, 11 December 2024
• Drugs@FDA: Inluriyo (imlunestrant), NDA 218881 — efficacy supplement approval record — U.S. Food and Drug Administration, approved 18 September 2026
• A Study of Imlunestrant in Participants With Advanced Breast Cancer (EMBER-3, NCT04975308) — ClinicalTrials.gov, US National Library of Medicine